Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Irina Dyagil, Hagop M Kantarjian, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 4442.

https://doi.org/10.1182/blood.V120.21.4442.4442

Published: 2012

Journal Articles

Response and Overall Survival Is Impaired in Obese Patients with Acute Myelogenous Leukemia

Martina Crysandt, MD, Edgar Jost, MD, Susanne Isfort, MD, Tim H Brümmendorf, Stefan Wilop, MD

Blood (2012) 120 (21): 1522.

https://doi.org/10.1182/blood.V120.21.1522.1522

Published: 2012

Journal Articles

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood (2012) 120 (21): 2012.

https://doi.org/10.1182/blood.V120.21.2012.2012

Published: 2012

Journal Articles

Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment

Fabian Beier, MD, Ralph P Schneider, MS, Guntram Buesche, MD, Jens Panse, MD, Ulrich Germing, Maria A Blasco, PhD, Tim H Brümmendorf

Blood (2012) 120 (21): 3809.

https://doi.org/10.1182/blood.V120.21.3809.3809

Published: 2012

Journal Articles

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Blood (2012) 120 (21): 3816.

https://doi.org/10.1182/blood.V120.21.3816.3816

Published: 2012

Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Anna G Turkina, Zhi-Xiang Shen, H. Jean Khoury, Tim H Brümmendorf, Philippe Schafhausen, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Tamas Masszi, Simon Durrant, Kimmo Porkka, MD, PhD, Eric Leip, Virginia Kelly, Nadine Besson, Carlo Gambacorti-Passerini

Blood (2012) 120 (21): 3779.

https://doi.org/10.1182/blood.V120.21.3779.3779

Published: 2012

Journal Articles

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Mirle Schemionek, PhD, Ulrich Steidl, MD, PhD, Albrecht Schwab, MD, Daniel G Tenen, MD, Copland Mhairi, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Christian Preisinger, PhD, Carsten Mueller-Tidow, MD, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 2776.

https://doi.org/10.1182/blood.V120.21.2776.2776

Published: 2012

Journal Articles

Comparative Analysis of Hematopoiesis Supporting Capacity and Matrix Remodeling of Bone Marrow Stromal Cells Isolated From Patients with Myeloproliferative Neoplasms.

Rebekka K Schneider, MD, Isabelle Leisten, Susanne Ziegler, PhD, Anne Schumacher, Dirk Fahrenkamp, Gerhard Mueller-Newen, PhD, Martina Crysandt, MD, Edgar Jost, MD, Ruth Knuechel, MD, Tim H Brümmendorf, Patrick Ziegler, PhD

Blood (2012) 120 (21): 2864.

https://doi.org/10.1182/blood.V120.21.2864.2864

Published: 2012

Journal Articles

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Jorge E. Cortes, MD, H. Jean Khoury, Jeff H Lipton, MD, Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Eric Leip, Virginia Kelly, Nadine Besson, Kathleen Turnbull, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2793.

https://doi.org/10.1182/blood.V120.21.2793.2793

Published: 2012

Journal Articles

Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.

Jorge E Cortes, MD, Tim H Brümmendorf, H. Jean Khoury, Andreas Hochhaus, MD, Jane Apperley, Stephen O'Brien, Eric Leip, Virginia Kelly, Katherine Ruffner, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2798.

https://doi.org/10.1182/blood.V120.21.2798.2798

Published: 2012

Journal Articles

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Tim H Brümmendorf, Hagop M. Kantarjian, MD, Carlo Gambacorti-Passerini, Francois Guilhot, Luke Akard, MD, Vaishali Doshi, Jeff H Lipton, MD, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 69.

https://doi.org/10.1182/blood.V120.21.69.69

Published: 2012

Journal Articles

Identification of Atypical Plasma Cells in Patients with MGUS or Multiple Myeloma Through Expression of Immunoreceptor CD229

Markus Ertmer, Djordje Atanackovic, Lucia Vankann, Stefan Wilop, MD, Eray Gökkurt, MD, Tim H Brümmendorf, Jens Panse, MD

Blood (2012) 120 (21): 4969.

https://doi.org/10.1182/blood.V120.21.4969.4969

Published: 2012

Journal Articles

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

Susanne Isfort, MD, Edgar Jost, MD, Karla Bennemann, MD, Martina Crysandt, MD, Sema Akin, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 5063.

https://doi.org/10.1182/blood.V120.21.5063.5063

Published: 2012

Journal Articles

MSCs From Patients with Myelofibrosis Display a Fibrotic Phenotype

Rebekka K Schneider, MD, Isabelle Leisten, Susanne Ziegler, PhD, Anne Schumacher, Tim H Brümmendorf, Edgar Jost, MD, Patrick Ziegler, PhD

Blood (2011) 118 (21): 5160.

https://doi.org/10.1182/blood.V118.21.5160.5160

Published: 2011

Journal Articles

Epigenetic Dysregulation of the Tissue Inhibitor of Metalloproteinases-2 Gene in Multiple Myeloma

Oliver Galm, Edgar Jost, MD, Claudia Schubert, James G. Herman, MD, Tim H Brümmendorf, Stefan Wilop, MD

Blood (2011) 118 (21): 5089.

https://doi.org/10.1182/blood.V118.21.5089.5089

Published: 2011

Journal Articles

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H Brümmendorf, Kimmo Porkka, MD, PhD, Giovanni Martinelli, MD, Simon Durrant, Eric Leip, Nadine Besson, Virginia Kelly, Carlo Gambacorti-Passerini, MD

Blood (2011) 118 (21): 2760.

https://doi.org/10.1182/blood.V118.21.2760.2760

Published: 2011

Journal Articles

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Tim H Brümmendorf, Patrick Ziegler, PhD, Jamil Akkad, MD, Ute Brassat, PhD, Lucia Vankann, Jens Panse, MD, Stefan Wilop, MD, Stefan Balabanov, MD, PhD, Klaus Schwarz, MD, Uwe M. Martens, MD, PhD, Hubert Schrezenmeier, MD

Blood (2011) 118 (21): 3427.

https://doi.org/10.1182/blood.V118.21.3427.3427

Published: 2011

Journal Articles

Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

H. Jean Khoury, Jorge E Cortes, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, Andrey Zaritskey, Andreas Hochhaus, MD, Eric Leip, Nadine Besson, Virginia Kelly, Tim H Brümmendorf

Blood (2011) 118 (21): 110.

https://doi.org/10.1182/blood.V118.21.110.110

Published: 2011

Journal Articles

The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial

Dong-Wook Kim, Jorge E Cortes, Zvenyslava Maslyak, Raymond Wong, Ladan Duvillie, Christine Powell, Athena Countouriotis, Tim H Brümmendorf

Blood (2011) 118 (21): 2769.

https://doi.org/10.1182/blood.V118.21.2769.2769

Published: 2011

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

NARROW

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Response and Overall Survival Is Impaired in Obese Patients with Acute Myelogenous Leukemia

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Accelerated Telomere Shortening Identifies a Subgroup of Patients with Myelodysplastic Syndrome and Isolated 5q Minus Deletion with a Higher Probability of Response to Lenalidomide Treatment

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Comparative Analysis of Hematopoiesis Supporting Capacity and Matrix Remodeling of Bone Marrow Stromal Cells Isolated From Patients with Myeloproliferative Neoplasms.

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Identification of Atypical Plasma Cells in Patients with MGUS or Multiple Myeloma Through Expression of Immunoreceptor CD229

Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]

MSCs From Patients with Myelofibrosis Display a Fibrotic Phenotype

Epigenetic Dysregulation of the Tissue Inhibitor of Metalloproteinases-2 Gene in Multiple Myeloma

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only